论文部分内容阅读
目的探讨HMGA2在原发性肝癌中的表达及其与原发性肝癌患者临床资料间的关系。方法通过RT-PCR检测HMGA2 mRNA在肝癌组织及正常肝组织中的表达,蛋白质印迹分析、免疫组化分别检测HMGA2蛋白在肝癌组织及正常肝组织中的表达水平,分析HMGA2蛋白的表达与肝癌患者临床资料之间的相关性。结果HMGA2 mRNA在肝癌组织中的阳性表达率为43.69%,高于在正常肝组织中23.30%的阳性表达率,其在肝癌组织中的相对表达值为0.71±0.03,高于其在正常肝组织中0.28±0.04的相对表达值(P<0.05)。HMGA2蛋白在肝癌组织中的相对表达值为0.56±0.04,高于其在正常肝组织中0.19±0.03的相对表达值(P<0.05)。免疫组化结果显示HMGA2蛋白在正常肝组织中阳性表达率为20.39%,明显低于其在肝癌组织中37.86%的阳性表达率(P<0.05),HMGA2蛋白的表达与肝癌患者性别和肿瘤大小无关(P>0.05),但与淋巴结转移数量、肝内转移以及临床分期相关(P<0.05或P<0.01)。结论HMGA2在肝癌组织中高表达,且其高表达与肝癌的淋巴结转移数量、肝内转移及临床分期紧密相关,可作为肝癌转移和恶化的肿瘤标志物。
Objective To investigate the expression of HMGA2 in primary hepatocellular carcinoma (HCC) and its relationship with clinical data of patients with primary liver cancer. Methods The expression of HMGA2 mRNA in HCC tissues and normal liver tissues was detected by RT-PCR. The expression of HMGA2 protein in HCC tissues and normal liver tissues were detected by Western blotting and immunohistochemistry. The expression of HMGA2 protein in hepatocellular carcinoma Correlation between clinical data. Results The positive expression rate of HMGA2 mRNA in HCC tissues was 43.69%, which was higher than that in normal liver tissues (23.30%). The relative expression value of HMGA2 mRNA in HCC tissues was 0.71 ± 0.03, which was higher than that in normal liver tissues In the relative expression value of 0.28 ± 0.04 (P <0.05). The relative expression value of HMGA2 in HCC tissues was 0.56 ± 0.04, which was higher than that in normal liver tissues (0.19 ± 0.03) (P <0.05). Immunohistochemical results showed that the positive expression rate of HMGA2 protein in normal liver tissue was 20.39%, which was significantly lower than that in HMMCC tissue (37.86%) (P <0.05). The expression of HMGA2 protein correlated with the gender and tumor size (P <0.05), but not with lymph node metastasis, intrahepatic metastasis and clinical stage (P <0.05 or P <0.01). Conclusion HMGA2 is overexpressed in HCC tissues, and its high expression is closely related to the number of metastatic lymph nodes, intrahepatic metastasis and clinical stage of HCC, and can be used as a tumor marker for the metastasis and deterioration of HCC.